Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J, Shirakawa K, Suzuki R, Kishimoto M, Kosugi Y, Kobiyama K, Hara T, Toyoda M, Tanaka YL, Butlertanaka EP, Shimizu R, Ito H, Wang L, Oda Y, Orba Y, Sasaki M, Nagata K, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Kuramochi J, Seki M, Fujiki R, Kaneda A, Shimada T, Nakada TA, Sakao S, Suzuki T, Ueno T, Takaori-Kondo A, Ishii KJ, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sawa H, Saito A, Irie T, Tanaka S, Matsuno K, Fukuhara T, Ikeda T, Sato K. Yamasoba D, et al. Among authors: kuramochi j. Cell. 2022 Jun 9;185(12):2103-2115.e19. doi: 10.1016/j.cell.2022.04.035. Epub 2022 May 2. Cell. 2022. PMID: 35568035 Free PMC article.
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, Yamasoba D, Gerber PP, Fatihi S, Rathore S, Zepeda SK, Papa G, Kemp SA, Ikeda T, Toyoda M, Tan TS, Kuramochi J, Mitsunaga S, Ueno T, Shirakawa K, Takaori-Kondo A, Brevini T, Mallery DL, Charles OJ; CITIID-NIHR BioResource COVID-19 Collaboration; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ecuador-COVID19 Consortium; Bowen JE, Joshi A, Walls AC, Jackson L, Martin D, Smith KGC, Bradley J, Briggs JAG, Choi J, Madissoon E, Meyer KB, Mlcochova P, Ceron-Gutierrez L, Doffinger R, Teichmann SA, Fisher AJ, Pizzuto MS, de Marco A, Corti D, Hosmillo M, Lee JH, James LC, Thukral L, Veesler D, Sigal A, Sampaziotis F, Goodfellow IG, Matheson NJ, Sato K, Gupta RK. Meng B, et al. Among authors: kuramochi j. Nature. 2022 Mar;603(7902):706-714. doi: 10.1038/s41586-022-04474-x. Epub 2022 Feb 1. Nature. 2022. PMID: 35104837 Free PMC article.
Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5.
Kimura I, Yamasoba D, Tamura T, Nao N, Suzuki T, Oda Y, Mitoma S, Ito J, Nasser H, Zahradnik J, Uriu K, Fujita S, Kosugi Y, Wang L, Tsuda M, Kishimoto M, Ito H, Suzuki R, Shimizu R, Begum MM, Yoshimatsu K, Kimura KT, Sasaki J, Sasaki-Tabata K, Yamamoto Y, Nagamoto T, Kanamune J, Kobiyama K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Shirakawa K, Takaori-Kondo A, Kuramochi J, Schreiber G, Ishii KJ; Genotype to Phenotype Japan (G2P-Japan) Consortium; Hashiguchi T, Ikeda T, Saito A, Fukuhara T, Tanaka S, Matsuno K, Sato K. Kimura I, et al. Among authors: kuramochi j. Cell. 2022 Oct 13;185(21):3992-4007.e16. doi: 10.1016/j.cell.2022.09.018. Epub 2022 Sep 14. Cell. 2022. PMID: 36198317 Free PMC article.
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.
Saito A, Tamura T, Zahradnik J, Deguchi S, Tabata K, Anraku Y, Kimura I, Ito J, Yamasoba D, Nasser H, Toyoda M, Nagata K, Uriu K, Kosugi Y, Fujita S, Shofa M, Monira Begum M, Shimizu R, Oda Y, Suzuki R, Ito H, Nao N, Wang L, Tsuda M, Yoshimatsu K, Kuramochi J, Kita S, Sasaki-Tabata K, Fukuhara H, Maenaka K, Yamamoto Y, Nagamoto T, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Ueno T, Schreiber G, Takaori-Kondo A; Genotype to Phenotype Japan (G2P-Japan) Consortium; Shirakawa K, Sawa H, Irie T, Hashiguchi T, Takayama K, Matsuno K, Tanaka S, Ikeda T, Fukuhara T, Sato K. Saito A, et al. Among authors: kuramochi j. Cell Host Microbe. 2022 Nov 9;30(11):1540-1555.e15. doi: 10.1016/j.chom.2022.10.003. Epub 2022 Oct 18. Cell Host Microbe. 2022. PMID: 36272413 Free PMC article.
Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant.
Ito J, Suzuki R, Uriu K, Itakura Y, Zahradnik J, Kimura KT, Deguchi S, Wang L, Lytras S, Tamura T, Kida I, Nasser H, Shofa M, Begum MM, Tsuda M, Oda Y, Suzuki T, Sasaki J, Sasaki-Tabata K, Fujita S, Yoshimatsu K, Ito H, Nao N, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Yamamoto Y, Nagamoto T, Kuramochi J, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium; Saito A, Matsuno K, Takayama K, Hashiguchi T, Tanaka S, Fukuhara T, Ikeda T, Sato K. Ito J, et al. Among authors: kuramochi j. Nat Commun. 2023 May 11;14(1):2671. doi: 10.1038/s41467-023-38188-z. Nat Commun. 2023. PMID: 37169744 Free PMC article.
Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5.
Kaku Y, Kosugi Y, Uriu K, Ito J, Hinay AA Jr, Kuramochi J, Sadamasu K, Yoshimura K, Asakura H, Nagashima M; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato K. Kaku Y, et al. Among authors: kuramochi j. Lancet Infect Dis. 2023 Oct;23(10):e395-e396. doi: 10.1016/S1473-3099(23)00553-4. Epub 2023 Sep 11. Lancet Infect Dis. 2023. PMID: 37708910 No abstract available.
Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.
Kosugi Y, Kaku Y, Hinay AA Jr, Guo Z, Uriu K, Kihara M, Saito F, Uwamino Y, Kuramochi J, Shirakawa K, Takaori-Kondo A; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato K. Kosugi Y, et al. Among authors: kuramochi j. Lancet Infect Dis. 2024 Mar;24(3):e147-e148. doi: 10.1016/S1473-3099(23)00784-3. Epub 2024 Jan 8. Lancet Infect Dis. 2024. PMID: 38211599 No abstract available.
Characteristics of the SARS-CoV-2 omicron HK.3 variant harbouring the FLip substitution.
Kosugi Y, Plianchaisuk A, Putri O, Uriu K, Kaku Y, Hinay AA Jr, Chen L, Kuramochi J, Sadamasu K, Yoshimura K, Asakura H, Nagashima M, Ito J; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato K. Kosugi Y, et al. Among authors: kuramochi j. Lancet Microbe. 2024 Apr;5(4):e313. doi: 10.1016/S2666-5247(23)00373-7. Epub 2024 Jan 11. Lancet Microbe. 2024. PMID: 38219759 Free article. No abstract available.
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, Arioka H, Yanai H, Kuramochi J, Ihara G, Chubachi K, Yanagisawa N, Nagura Y, Kato Y, Ueda A, Numata A, Kato H, Ishii K, Ooki T, Oka H, Nishida Y, Stucky A, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Arashiro T, et al. Among authors: kuramochi j. Clin Infect Dis. 2023 Feb 8;76(3):e108-e115. doi: 10.1093/cid/ciac635. Clin Infect Dis. 2023. PMID: 35918782 Free PMC article.
36 results